Study product Indication Objective N Admin. frequency Comparator Results vs comparator MF 0.1 % O/W 33 % water content Cream Healthy Skin [12] Bioavailability (VCA) 31 Single application Vehicle Superiority Class II lower strength Non-inferiority Mometasone comparator Non-inferiority Class IV higher strength Non-inferiority (not confirmed) Tolerability 33 QD 21 days Vehicle   Purified water (negative control) Higher irritation score SDS (positive control) Lower irritation score Plaque Psoriasis [12] Efficacy 22 QD 12 days Vehicle Superiority Mometasone comparator Comparable Atopic Dermatitis [67] Efficacy QoL Patient satisfaction 20 QD 2 weeks Mometasone comparator Comparable efficacy Better cosmetic traits and patient satisfaction MF 0.1 % 36 % water content Emulsion Plaque Psoriasis [68] Efficacy and  Tolerability 24 QD 12 days Placebo emulsion Superiority Reference product cream Comparable Chronic Scalp Psoriasis [69] Efficacy 70 QD 3 weeks Reference product solution Non-inferiority QD: Once daily; Mometasone comparator: the originator mometasone furoate 0.1 % cream formulation (water content <5 %); Class II: 1 mg/g of triamcinolone acetonide (water content 72.2 %); Class IV: 0.5 mg/ml of clobetasol-17-propionate (water content 30.8 %); SDS: 0.3 % sodium dodecyl sulfate in water

Table 2: Summary of clinical trials evaluating the new mometasone formulations O/W cream (33 % water content) and emulsion (36 % water content).